$596 Million is the total value of FRAZIER MANAGEMENT LLC's 20 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 15.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PHAT | New | PHATHOM PHARMACEUTICALS INC | $226,832,000 | – | 7,284,269 | +100.0% | 38.04% | – |
| MIRM | MIRUM PHARMACEUTICALS INC | $87,461,000 | +143.7% | 3,566,912 | 0.0% | 14.67% | +30.8% | |
| KRYS | KRYSTAL BIOTECH INC | $49,565,000 | +59.5% | 895,000 | 0.0% | 8.31% | -14.4% | |
| IOVA | IOVANCE BIOTHERAPEUTICS INC | $48,458,000 | +52.1% | 1,750,665 | 0.0% | 8.13% | -18.4% | |
| COLL | COLLEGIUM PHARMACEUTICAL INC | $38,841,000 | +79.3% | 1,887,332 | 0.0% | 6.51% | -3.8% | |
| ANAB | ANAPTYSBIO INC | $37,642,000 | -53.6% | 2,316,447 | 0.0% | 6.31% | -75.1% | |
| GRTS | GRITSTONE ONCOLOGY INC | $18,494,000 | +3.9% | 2,061,758 | 0.0% | 3.10% | -44.3% | |
| TBIO | TRANSLATE BIO INC | $17,768,000 | -17.9% | 2,182,789 | 0.0% | 2.98% | -55.9% | |
| APTX | APTINYX INC | $10,910,000 | -2.0% | 3,190,079 | 0.0% | 1.83% | -47.4% | |
| ALPN | ALPINE IMMUNE SCIENCES INC | $9,874,000 | -3.0% | 2,571,450 | 0.0% | 1.66% | -48.0% | |
| MLND | MILLENDO THERAPEUTICS INC | $9,413,000 | -5.2% | 1,396,615 | 0.0% | 1.58% | -49.1% | |
| ALNA | ALLENA PHARMACEUTICALS INC | $9,092,000 | -30.7% | 3,330,373 | 0.0% | 1.52% | -62.8% | |
| ITRM | ITERUM THERAPEUTICS PLC | $6,922,000 | -22.0% | 1,538,316 | 0.0% | 1.16% | -58.2% | |
| ETTX | ENTASIS THERAPEUTICS HLDGS I | $6,709,000 | -16.6% | 1,349,953 | 0.0% | 1.12% | -55.3% | |
| NABRIVA THERAPEUTICS PLC | $5,619,000 | -34.0% | 4,256,526 | 0.0% | 0.94% | -64.6% | ||
| CDTX | CIDARA THERAPEUTICS INC | $5,039,000 | +92.5% | 1,312,258 | 0.0% | 0.84% | +3.2% | |
| ADVM | New | ADVERUM BIOTECHNOLOGIES INC | $3,091,000 | – | 268,343 | +100.0% | 0.52% | – |
| SRRA | SIERRA ONCOLOGY INC | $2,778,000 | -12.3% | 8,112,121 | 0.0% | 0.47% | -52.9% | |
| BLCM | BELLICUM PHARMACEUTICALS INC | $1,356,000 | +22.8% | 1,051,441 | 0.0% | 0.23% | -34.2% | |
| KZR | Sell | KEZAR LIFE SCIENCES INC | $363,000 | -76.3% | 90,578 | -80.6% | 0.06% | -87.3% |
| SYBX | Exit | SYNLOGIC INC | $0 | – | -282,649 | -100.0% | -0.20% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-13
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL INC | 21 | Q4 2020 | 37.0% |
| ANAPTYSBIO INC | 20 | Q4 2021 | 63.7% |
| CIDARA THERAPEUTICS INC | 20 | Q3 2020 | 17.2% |
| IOVANCE BIOTHERAPEUTICS INC | 19 | Q4 2021 | 13.7% |
| ALLENA PHARMACEUTICALS INC | 18 | Q1 2022 | 11.9% |
| ALPINE IMMUNE SCIENCES INC | 18 | Q4 2021 | 9.1% |
| APTINYX INC | 15 | Q4 2021 | 16.9% |
| KRYSTAL BIOTECH INC | 14 | Q4 2021 | 9.7% |
| GRITSTONE ONCOLOGY INC | 14 | Q4 2021 | 8.2% |
| SIERRA ONCOLOGY INC | 12 | Q4 2019 | 6.6% |
View FRAZIER MANAGEMENT LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-10 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-08 |
| 13F-HR | 2021-11-12 |
| 13F-HR | 2021-08-11 |
| 13F-HR | 2021-05-12 |
| 13F-HR | 2021-02-11 |
| 13F-HR | 2020-11-12 |
| 13F-HR | 2020-08-04 |
View FRAZIER MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.